home / stock / aplt / aplt news


APLT News and Press, Applied Therapeutics Inc. From 01/05/24

Stock Information

Company Name: Applied Therapeutics Inc.
Stock Symbol: APLT
Market: NYSE
Website: appliedtherapeutics.com

Menu

APLT APLT Quote APLT Short APLT News APLT Articles APLT Message Board
Get APLT Alerts

News, Short Squeeze, Breakout and More Instantly...

APLT - RCAC, AIMD and MESO among mid-day movers

2024-01-05 12:31:54 ET Gainers: Revelstone Capital Acquisition Corp ( RCAC ) +90% . Ainos ( AIMD ) +72% . Banzai International ( BNZI ) +62% . Safe and Green Development ( SGD ) +41% . Swvl Holdings ( SWVL ) +41% . Zoomcar Ho...

APLT - Cyclacel Pharmaceuticals, Angiodynamic among healthcare movers

2024-01-05 10:00:03 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...

APLT - Biggest stock movers today: Peloton, Medical Properties Trust, and more

2024-01-05 05:29:04 ET Stock futures inched lower in the early hours of Friday ahead of the December jobs report. Here are some of Friday's biggest stock movers: Biggest stock gainers For further details see: Biggest stock movers today: Peloton, Medical Properties Trust, and...

APLT - Applied Therapeutics stock plunges 30% on Phase 3 data for cardiac drug

2024-01-04 18:14:29 ET More on Applied Therapeutics ARISE-HF Phase 3 Trial Likely To Disappoint Due To Multiple Red Flags Applied Therapeutics: Multiple Inflection Points Could Generate Substantial Value Applied Therapeutics: Capital Raise Forthcoming Applied...

APLT - Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months AT-001 treatment resulted in a statistically significant difference in cardiac functional capacity in a prespecified subgroup of patients not rece...

APLT - ARISE-HF Phase 3 Trial Likely To Disappoint Due To Multiple Red Flags

2024-01-04 11:37:10 ET Summary Applied Therapeutics has encountered significant valuation challenges since its IPO, primarily due to the limited efficacy of its Aldose Reductase Inhibitors (ARI) franchise. The company is expected to release topline data from ARISE-HF, a phase 3 tr...

APLT - Applied Therapeutics: Multiple Inflection Points Could Generate Substantial Value

2024-01-04 05:19:37 ET Summary EMA validated and accepted the regulatory application of govorestat for the treatment of patients with galactosemia; the FDA has a 60-day review period to look at the application for validation and acceptance. Release of results from the phase 3 ARIS...

APLT - Applied Therapeutics stock jumps 10% on FDA, EMA submissions

2024-01-03 10:55:34 ET More on Applied Therapeutics Applied Therapeutics: Capital Raise Forthcoming Seeking Alpha’s Quant Rating on Applied Therapeutics Historical earnings data for Applied Therapeutics Financial information for Applied Therapeutics ...

APLT - Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia

NDA submitted to FDA and MAA validated by EMA in December 2023 Submissions are based on positive results from Phase 3 registrational ACTION-Galactosemia Kids study demonstrating consistent long-term clinical outcomes benefit across a range of functional measures and favorable safety profi...

APLT - Corcept Therapeutics, Adc Therapeutics among healthcare movers

2024-01-02 10:00:09 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...

Previous 10 Next 10